Corvus Pharmaceuticals (NASDAQ: CRVS)
$7.37
(1.2%)
$0.09
Price as of September 30, 2025, 4:00 p.m. ET
Corvus Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Corvus Pharmaceuticals Company Info
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.